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Jae Myun Chung15, Heui‑Soo Moon3, Chin‑Sang Chung5, Kwang‑Yeol Park16 & Soo‑Jin Cho17* 
Although cranial autonomic symptoms (CAS) are typical in cluster headache (CH), some individuals 
with CH show no CAS during their headache attacks. Probable cluster headache (PCH) is a subtype of 
CH that fulfils all but one criterion of CH. This study aimed to investigate the frequency and clinical 
features of CH and PCH without CAS in comparison to those with CAS. We analysed data from the 
Korea Cluster Headache Registry, a prospective multicentre registry involving data from 16 hospitals. 
Of the 216 participants with CH and 26 with PCH, 19 (8.8%) and 7 (26.9%), respectively, did not have 
CAS. Participants with CH without CAS exhibited less severe anxiety (General Anxiety Disorder‑7 
score, median [interquartile range], 2.0 [1.0–6.0] vs 8.0 [3.0–12.0], p = 0.001) and depression (Patient 
Health Questionnaire‑9 score, 3.0 [1.0–7.0] vs 7.0 [3.0–11.0], p = 0.042) than those with CAS. Among 
participants with PCH, headache intensity was less severe in participants without CAS than in those 
with CAS (numeric rating scale, 8.0 [7.0–8.0] vs 9.5 [8.0–10.0], p = 0.015). In conclusion, a significant 
proportion of participants with CH and PCH did not have CAS. Some clinical features of CH and PCH 
differed based on the presence of CAS.
Cluster headache (CH) is characterised by recurrent severe unilateral headache attacks and is accompanied by 
ipsilateral cranial autonomic symptoms (CAS)1,2. The term CH originates from the tendency of headache attacks 
to cluster during cluster periods that usually last for several weeks to  months3. The third edition of the Interna-
tional Classification of Headache Disorders (ICHD-3) has divided the CH population into CH (code 3.1) and 
probable CH (PCH; code 3.5.1)2. PCH is a subtype of CH that fulfils all but one of the five criteria for CH and 
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was reported to account for approximately 10–20% of CH  cases2,4,5. Some clinical features of PCH differ from 
those of CH. Individuals with PCH have a lower incidence of conjunctival injection and forehead sweating than 
those with CH, but these groups have showed comparable  disability5,6.
Although CAS have been recognised as typical symptoms of CH, 3–7% of individuals with CH were noted to 
never experience CAS during their CH  attacks7–9. The frequency and clinical features of CH without CAS have 
been reported in only one instance. A Portuguese study from a single university hospital reported in 2005 that 
headache intensity was less severe in individuals with CH without CAS than in those with  CAS7. However, since 
this study did not distinguish between CH and PCH in its analysis, the frequency and clinical features of CH 
and PCH without CAS compared to those with CAS remain unclear. Furthermore, this study used data from a 
single hospital; thus, an additional analysis using data from various settings is needed to validate these findings.
This study aimed to assess (1) the frequencies of CH and PCH without CAS among participants with CH and 
PCH and (2) the differences in the clinical features of participants with CH and PCH with and without CAS. 
For this purpose, we used data from the Korean Cluster Headache Registry (KCHR), a prospective, multicentre 
registry of CH.
Methods
Study design and participants. This descriptive, cross-sectional study aimed to investigate the frequency 
and clinical features of CH and PCH without CAS using data from the KCHR. The KCHR enrolled consecutive 
participants with CH aged ≥ 19 years from 16 hospitals (14 university hospitals and two secondary referral gen-
eral hospitals) in Korea. Participants were enrolled between September 2016 and December 2018.
Detailed information about the KCHR has been described  previously5,10. In the KCHR, participants fulfilling 
the available diagnostic criteria for CH and PCH, the third edition beta version of the International Classifica-
tion of Headache Disorders (ICHD-3 beta), at the time it was created were  enrolled11. For the present study, we 
included participants fulfilling the diagnostic criteria for CH and PCH based on ICHD-32. A flow diagram of 
the participant selection process is presented in Fig. 1.
The KCHR collected data on the following parameters for all participants: sex, age at onset of CH, height, 
weight, headache intensity on numeric rating scale (from 0 to 10), CH attack frequency per day, mean CH dura-
tion since the first cluster period, cluster period duration during the ictal period, total number of cluster periods, 
smoking status, impact of headache (Headache Impact Test-6 score), circadian and circannual rhythmicity of 
headache attacks, quality of life (the 3-level version of EuroQol five-dimension scale [EQ-5D-3L]), anxiety 
(Generalized Anxiety Disorder [GAD-7] score), and depression (Patient’s Health Questionnaire-9 [PHQ-9] 
score)12,13. Participants with a GAD-7 score of ≥ 10 were classified as having anxiety, while participants with a 
PHQ-9 score of ≥ 10 were classified as having  depression12,14. The previously validated Korean versions of PHQ-9, 
GAD-7 and EQ-5D-3L were  used14–16. The cluster period was designated as CH attacks occurring in a series for 
weeks to months, separated by remission periods, usually lasting months or years. The cluster period duration 
was defined as the duration between the first and last days of each cluster period. The total number of cluster 
Figure 1.  Flow diagram of participant selection. CH cluster headache, ICHD-3 The third edition of the 
International Classification of Headache Disorders, ICHD-3 beta The third edition beta version of the 
International Classification of Headache Disorders, PCH probable cluster headache.
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periods was defined as the total number of cluster periods diagnosed as CH. Migraine history was evaluated in 
all participants. Investigators assessed the circadian and circannual rhythmicity of headache attacks by asking 
participants whether the CH attacks in cluster periods tended to occur at the same time of the day and year, 
respectively.
Diagnosis of CH and PCH. The diagnoses of CH and PCH were based on the ICHD-3  criteria2. We further 
classified participants into one of the following groups based on the cluster period duration: no definitive period, 
episodic, or chronic. Participants whose first episode of headache attacks fulfilled the CH or PCH criteria were 
classified, respectively, as having CH or PCH without a definitive period. Participants whose CH or PCH attacks 
lasted at least 1 year without a remission period or with remissions lasting < 3 months were classified as having 
chronic CH (CCH) or PCH, respectively. Participants whose CH or PCH attacks occurred in cluster periods, in 
whom two or more cluster periods lasted from 7 days to 1 year when untreated, and in whom cluster periods 
were separated by pain-free remission periods of ≥ 3 months were classified as having episodic CH (ECH) or 
episodic PCH.
Case definitions of CH and PCH without CAS. According to the ICHD-3, we evaluated CAS in par-
ticipants with CH and PCH based on the presence of the following conditions: (1) conjunctival injection and/or 
lacrimation, (2) nasal congestion and/or rhinorrhoea, (3) eyelid oedema, (4) forehead and facial sweating, and 
(5) miosis and/or ptosis. Since our study started in September 2016, when only the ICHD-3 beta was available, 
we also assessed the presence of (1) a sensation of fullness in the ear and (2) forehead and facial flushing, which 
were included as CAS in the ICHD-3 beta but not in the ICHD-32,11.
Ethical considerations. The institutional review boards of the 16 participating hospitals (Severance Hos-
pital, Bundang Jesaeng General Hospital, Uijeongbu St.Mary’s Hospital, Chuncheon Sacred Heart Hospital, 
Samsung Medical Center, Eulji Hospital, Seoul Medical Center, Presbyterian Medical Center, Ewha Womans 
University Mokdong Hospital, Kangbuk Samsung Hospital, Korea University Kuro Hospital, Seoul St. Mary’s 
Hospital, Gyeongsang National University Hospital, Chung-Ang University Hospital, Seoul Paik Hospital, and 
Dongtan Sacred Heart Hospital) approved this study. All participants provided written informed consent before 
study enrolment. All clinical investigations were conducted following the principles expressed in the Declaration 
of Helsinki and its following amendments.
Statistical analyses. The Shapiro–Wilks test was used to evaluate the normality of data distribution. When 
a normal distribution was confirmed, Student’s t test was used to compare continuous variables. If a normal 
distribution was not confirmed, the Mann–Whitney U test was used, and values were expressed as medians 
(interquartile ranges). The chi-squared test was used to evaluate categorical variables. If an expected value was 
less than five, Fisher’s exact test was used instead of the chi-squared test. Results were considered statistically sig-
nificant when two-tailed p values were less than 0.05. The sample size was based on the available data. Statistical 
analyses were performed using IBM SPSS Statistics for Windows, Version 23.0 (IBM Corp., Armonk, NY, USA).
Results
Participants. A total of 251 participants were enrolled. One participant was excluded for not fulfilling the 
ICHD-3 criteria, and eight were excluded due to incomplete data. Finally, 216 participants with CH and 26 
participants with PCH were included in this study (Fig. 1). The reasons for a diagnosis of PCH were as follows: 
an atypical attack duration (n = 8, 30.7%), where the duration was longer (n = 6) or shorter (n = 1) than typical; 
missing accompanying symptoms (n = 6, 23.1%); < 5 total number of attacks (n = 5, 19.2%); < 1 attack every other 
day (n = 3, 11.5%); not a severe headache intensity (n = 2, 7.7%); and a bilateral pain location (n = 2, 7.7%). None 
of the participants with CH or PCH without CAS had a sensation of fullness in the ear or forehead and facial 
flushing, which were included as CAS in ICHD-3  beta11.
The frequencies of CAS in participants with CH and PCH are summarised in Table 1. Conjunctival injection 
and/or lacrimation was the most common CAS in participants with CH, followed by nasal congestion and/or 
rhinorrhoea. Sensation of fullness in the ear was the least common CAS, and ptosis or miosis was the second 
less common CAS. Similar patterns were seen in participants with PCH, with conjunctival injection and/or 
lacrimation being the most common CAS and ptosis or miosis being the least common.
Clinical features of all participants according to the presence of CAS. The clinical features of all 
242 participants are summarised in Table 2. The headache intensity was less severe in participants without CAS 
than in those with CAS. Anxiety (GAD-7 score ≥ 10) and depression (PHQ-9 score ≥ 10) were less prevalent 
in participants without CAS than in those with CAS. All other features were similar in participants with and 
without CAS.
Clinical features of participants with CH based on the presence of CAS. Of the 216 participants 
with CH, 19 (8.8%) did not have CAS. Anxiety and depression were less severe in participants with CH without 
CAS than in those with CAS. Other characteristics were not associated with the presence of CAS (Table 3).
Among the 172 participants with ECH, 15 (8.7%) did not have CAS. Anxiety and depression were less 
prevalent in participants with ECH without CAS than in those with CAS. The average cluster period duration 
in months was longer in those with ECH without CAS than in those with CAS. Other clinical features were 
similar between participants with ECH with and without CAS (Table 4). Of the 12 participants with CCH, two 
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Table 1.  Distribution of accompanying symptoms in the participants. CH cluster headache, PCH probable 
cluster headache, ECH episodic cluster headache, CCH chronic cluster headache.
Accompanying symptoms
All participants with CH or 
PCH n = 242, n (%)
CH (code 3.1, 3.1.1, and 
3.1.2) n = 216, n (%)
ECH (code 3.1.1) n = 172, 
n (%)
CCH (code 3.1.2) n = 12, 
n (%)
PCH (code 3.5.1) n = 26, 
n (%)
Cranial autonomic symptoms
 Conjunctival injection and/
or lacrimation 202 (83.5) 187 (86.6) 151 (87.8) 11 (91.7) 15 (57.7)
 Nasal congestion and/or 
rhinorrhoea 134 (55.4) 123 (56.9) 110 (64.0) 3 (25.0) 11 (42.3)
 Eyelid oedema 64 (26.4) 60 (27.8) 50 (29.1) 3 (25.0) 4 (15.4)
 Forehead and facial sweating 68 (28.1) 66 (30.6) 54 (31.4) 5 (41.7) 2 (7.7)
 Miosis and/or ptosis 50 (20.7) 48 (22.2) 39 (22.7) 2 (13.3) 2 (7.7)
 Forehead and facial flushing 38 (15.7) 37 (17.1) 34 (19.8) 1 (8.3) 1 (3.8)
 Sensation of fullness in 
the ear 22 (9.1) 20 (9.3) 19 (11.0) 0 (0.0) 2 (7.7)
Non-cranial autonomic symptom
 A sense of restlessness or 
agitation 116 (47.9) 107 (49.5) 85 (49.4) 8 (66.7) 9 (34.6)
 Participants without cranial 
autonomic symptoms 26 (10.7) 19 (8.8) 15 (8.7) 1 (8.3) 7 (26.9)
Table 2.  Clinical features of participants with CH and PCH according to the presence of CAS. CAS cranial 
autonomic symptoms, CH cluster headache, EQ-5D-3L the 3-level version of EuroQol five-dimension scale, 
IQR interquartile range, PCH probable cluster headache.
Participants with CH and PCH n = 242, 
n (%)
Participants with CH and PCH with 
CAS n = 216, n (%)
Participants with CH and PCH 
Without CAS n = 26, n (%) p value
Female, n (%) 37 (15.3) 33 (15.3) 4 (15.4) 1.000
Age (year), median and IQR 37 (30.0–44.0) 37.0 (30.3–43.8) 37.0 (28.8–44.3) 0.822
Height (cm), median and IQR 174.0 (169.0–178.0) 174.0 (169.3–178.0) 172.0 (168.8–175.3) 0.095
Weight (Kg), median and IQR 72.0 (64.8–79.3) 72.0 (64.0–79.8) 70.5 (65.8–77.8) 0.421
Attack frequency per day, median and 
IQR 1.4 (1.0–3.0) 1.5 (1.0–3.0) 1.0 (1.0–2.1) 0.686
Headache intensity (numeric rating 
scale), median and IQR 9.0 (8.0–9.0) 9.0 (8.0–10.0) 8.3 (8.0–10.0) 0.303
Attack duration (minutes), median and 
IQR 80.0 (60.0–120.0) 77.5 (60.0–120.0) 90.0 (60.0–120.0) 0.796
Migraine history, n (%) 33 (13.6) 30 (14.30) 3 (11.5) 1.000
Circadian rhythmicity in headache 
attacks, n (%) 134 (55.4) 121 (56.0) 13 (50.0) 0.560
Circannual rhythmicity in headache 
attacks, n (%) 219 (90.5) 198 (91.7) 21 (80.8) 0.073
Current smoking, n (%) 106 (43.8) 99 (45.8) 7 (26.9) 0.066
Location of pain
 Orbital, n (%) 193 (79.8) 174 (80.6) 19 (73.1) 0.370
 Supraorbital, n (%) 121 (50.0) 112 (51.9) 9 (34.6) 0.097
 Temporal, n (%) 138 (57.0) 121 (56.0) 17 (65.4) 0.362
 Headache Impact Test-6 score, median 
and IQR 69.0 (63.0–75.0) 69.0 (63.0–75.0) 67.5 (57.8–72.8) 0.259
 Anxiety (Generalized Anxiety Disor-
der-7 score), median and IQR 7.0 (3.0–11.0) 7.0 (3.0–12.0) 2.0 (1.0–7.5) 0.001
 Generalized Anxiety Disorder-7 
score ≥ 10, n (%) 87 (36.0) 83 (38.8) 4 (15.4) 0.018
 Depression (Patient Health Question-
naire-9 score), median and IQR 6.0 (3.0–11.0) 7.0 (3.0–11.0) 4.0 (2.0–7.3) 0.029
 Patient Health Questionnaire-9 
score ≥ 10, n (%) 80 (33.1) 76 (35.3) 4 (15.4) 0.047
 Quality of life (EQ-5D-3L), median 
and IQR 0.913 (0.819–1.000) 0.907 (0.774–1.000) 0.913 (0.868–1.000) 0.248
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(16.7%) did not have CAS. The frequencies of the absence of CAS in ECH and CCH were similar (8.7% [15/172] 
vs 16.7% [2/12], p = 0.612).
Clinical features of participants with PCH based on the presence of CAS. Of the 26 participants 
with PCH, 7 (26.9%) did not have CAS. Headache intensity was less severe in participants with PCH without 
CAS than in those with CAS. The prevalence of anxiety and depression and other clinical features were similar 
in participants with PCH with and without CAS (Table 5). The frequency of not having CAS was higher in par-
ticipants with PCH than in those with CH (26.9% [7/26] vs 8.7% [19/216], p = 0.005).
Discussion
The main findings of the present study were as follows: (1) Approximately one-eleventh of participants with CH 
and a quarter of those with PCH did not have CAS; (2) Anxiety and depression were less severe in participants 
with CH without CAS than in those with CAS; and (3) Headache intensity was milder in participants with PCH 
without CAS than in those with CAS. Other clinical features of CH and PCH did not differ between participants 
with and without CAS.
CH has been characterised by recurrent attacks of severe unilateral headache and ipsilateral  CAS1,17. CAS 
were considered a key characteristic of CH and included as a diagnostic criterion since the publishing of the first 
edition of the  ICHD8,18. Nevertheless, it has been reported that some individuals with CH-like headaches did 
not experience CAS during headache  attacks9,19. The second edition of the ICHD, published in 2004, included 
a sense of restlessness or agitation as an accompanying symptom of CH, in addition to CAS, and a diagnosis of 
CH without CAS became  possible4. The subsequent editions of diagnostic criteria for CH retained restlessness or 
agitation as an accompanying symptom along with  CAS2,11. Therefore, CH and PCH without CAS are currently 
included in the ICHD-3, and our study enrolled participants based on these definitions.
We found that 8.8% of participants with CH did not have CAS. This frequency was similar or somewhat 
higher than that found in previous studies. A case series of 163 patients with CH in Sweden found that 3.1% of 
the patients did not have  CAS19, while an Italian clinic-based study of 251 patients with CH found that 2.8% of 
the patients did not have  CAS8. Another Italian study found that 7.5% of patients with CH did not have  CAS9. 
In a clinic-based study in Portugal, not having CAS was reported in 6.1% of patients with CH or  PCH7. Possible 
causes for the discrepancy between the findings from our study and those from previous studies include dif-
ferences in the diagnostic criteria, ethnicity, and study setting. The abovementioned Swedish study used three 
criteria for CH diagnosis (World Federation of Neurology, Ekbom, and ICHD-1)18,20,21. The two Italian studies 
used the ICHD-1, which did not include restlessness and agitation as accompanying symptoms. All four studies 
were conducted in European countries, while our study was conducted in Korea. Individuals with CH in Asian 
Table 3.  Clinical features of participants with CH according to the presence of CAS. CAS cranial autonomic 
symptoms, CH cluster headache, EQ-5D-3L the 3-level version of EuroQol five-dimension scale, IQR 
interquartile range.
Participants with CH
n = 216
Participants with CH with CAS
n = 197
Participants with CH without CAS
n = 19 p value
Female, n (%) 30 (13.9) 29 (14.7) 1 (5.3) 0.484
Age (year), n (%) 37.0 (30.0–44.0) 37.0 (30.0–43.5) 38.0 (25.0–45.0) 0.933
Height (cm), median and IQR 173.5 (170.0–178.0) 174.0 (170.0–178.0) 172.0 (169.0–176.0) 0.376
Weight (Kg), median and IQR 72.0 (64.3–79.0) 72.0 (64.0–79.0) 71.0 (66.0–80.0) 0.879
Attack frequency per day, median and IQR 1.5 (1.0–3.0) 1.5 (1.0–3.0) 1.5 (1.0–2.5) 0.686
Headache intensity (numeric rating scale), median and IQR 9.0 (8.0–10.0) 9.0 (8.0–10.0) 9.0 (8.0–10.0) 0.303
Attack duration (minutes), median and IQR 90.0 (60.0–120.0) 90.0 (60.0–120.0) 120.0 (60.0–120.0) 0.581
Migraine history, n (%) 28 (13.0) 27 (13.7) 1 (5.3) 0.479
Circadian rhythmicity in headache attacks, n (%) 125 (57.9) 116 (59.5) 9 (47.4) 0.306
Circannual rhythmicity in headache attacks, n (%) 197 (91.2) 181 (92.3) 16 (84.2) 0.221
Current smoking, n (%) 98 (45.4) 91 (46.2) 7 (36.8) 0.434
Location of pain
 Orbital, n (%) 172 (79.6) 158 (80.2) 14 (73.7) 0.500
 Supraorbital, n (%) 109 (50.5) 102 (51.8) 7 (36.8) 0.214
 Temporal, n (%) 120 (55.6) 110 (55.8) 10 (52.6) 0.788
 Headache Impact Test-6 score, median and IQR 69.0 (63.0–75.0) 69.0 (63.0–75.0) 70.0 (64.0–76.0) 0.938
 Anxiety (Generalized Anxiety Disorder-7 score), median and IQR 7.0 (3.0–11.75) 8.0 (3.0–12.0) 2.0 (1.0–6.0) 0.002
 Generalized Anxiety Disorder-7 score ≥ 10, n (%) 81 (37.5) 78 (39.6) 3 (15.8) 0.048
 Depression (Patient Health Questionnaire-9 score), median and 
IQR 6.0 (3.0–11.0) 7.0 (3.0–11.0) 3.0 (1.0–7.0) 0.030
 Patient Health Questionnaire-9 score ≥ 10, n (%) 71 (32.9) 68 (34.5) 3 (15.8) 0.126
 Quality of life (EQ-5D-3L), median and IQR 0.907 (0.819–1.000) 0.903 (0.785–1.000) 0.913 (0.870–1.000) 0.272
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countries showed lower attack frequencies and shorter attack durations than those in Western  countries22. All 
four previous studies used data from a single hospital, while the present study used data from the KCHR, which 
contained data from 16 hospitals.
It has been consistently reported that individuals with CH have a higher frequency of anxiety and depression 
than those with migraine or without  headache10,23–27. Additionally, it has been demonstrated that individuals 
with CCH are more likely to be affected by anxiety and depression than those with  ECH10. High frequencies of 
anxiety and depression were observed in the CH and PCH groups in the present study. Furthermore, to the best 
of our knowledge, this study is the first to report that anxiety and depression were less severe in participants 
with CH without CAS than in those with CAS. What is the possible mechanism underlying the association of 
anxiety and depression with CAS? One possible explanation is the role of shared anatomical substrates between 
the affective symptoms and CH in the pathogenesis of CAS. Neuroimaging findings have revealed an altered 
metabolism of the pain matrix and hypothalamus in patients with CH and affective  disorders28–30. Therefore, 
decreased frequencies of anxiety and depression in participants with CH without CAS may be related to the 
roles of the pain matrix and hypothalamus in the pathogenesis of CAS. This hypothesis could be evaluated by 
comparing the neuroimaging findings between individuals with CH with and without CAS.
Parasympathetic activation mediated by the trigeminal-autonomic reflex has been ascertained as the mecha-
nism for the presentation of CAS in  CH31. The trigeminal-autonomic reflex is a brainstem connection between 
the trigeminal nerve and facial cranial parasympathetic nerve outflow, which is activated by the stimulation 
of the trigeminovascular  system32. The hypothalamus has been hypothesised to play a role in initiating CH 
attacks and causing the activation of the trigeminovascular  system33,34. Once triggered, this system stimulates the 
trigeminal-autonomic reflex and results in the occurrence of  CAS35. The present study found that approximately 
9% of individuals with CH did not have CAS; these individuals had less anxiety and depression, which are closely 
related with the hypothalamus, compared to those with CAS. These findings suggest that some individuals with 
CH may have a weaker signal from the hypothalamus, which causes headache attacks but does not produce CAS. 
The weaker signal induces less anxiety and depression in individuals with CH. Our findings also suggest that the 
activation of the trigeminal-autonomic reflex is not an essential part of CH attacks.
Table 4.  Clinical features of participants with ECH according to the presence of CAS. CAS cranial autonomic 
symptoms, ECH episodic cluster headache, EQ-5D-3L the 3-level version of EuroQol five-dimension scale, IQR 
interquartile range.
Participants with ECH
n = 172
Participants with ECH with CAS
n = 157
Participants with ECH without CAS
n = 15 p value
Female, n (%) 22 (12.8) 21 (13.4) 1 (6.7) 0.696
Age (year), median and IQR 37 (30.25–44.0) 37.0 (31.5–44.0) 38.0 (24.0–44.0) 0.565
Onset age (year), median and IQR 10.0 (5.0–16.0) 10.0 (5.0–16.0) 60. (2.0–10.0) 0.067
Height (cm), median and IQR 174.0 (170.0–178.0) 175.0 (17.0–178.0) 172.0 (169.0–177.0) 0.305
Weight (Kg), median and IQR 72.0 (65.0–79.0) 72.0 (64.0–79.0) 70.0 (66.0–80.0) 0.698
Cluster duration (year), median and IQR 7.0 (3.0–12.0) 7.0 (3.0–12.0) 7.0 (2.0–10.0) 0.263
Total number of cluster periods, median and IQR 7.0 (3.0–12.0) 7.0 (3.0–12.0) 7.0 (2.0–10.0) 0.263
Attack frequency per day, median and IQR 1.4 (1.0–3.0) 1.5 (1.0–3.0) 1.0 (1.0–2.0) 0.383
Headache intensity (numeric rating scale), median and IQR 9.5 (8.0–10.0) 10.0 (8.5–10.0) 9.0 (8.0–10.0) 0.153
Attack duration (minutes), median and IQR 60.0 (60.0–120.0) 60.0 (60.0–120.0) 90.0 (35.0–120.0) 0.688
Average cluster period duration (month), median and IQR 4.0 (3.0–8.0) 4.0 (3.0–7.0) 6.0 (4.0–10.0) 0.020
Average remission period (month), median and IQR 12.0 (10.0–24.0) 12.0 (10.0–24.0) 12.0 (6.0–12.0) 0.502
Regular attack pattern, n (%) 121 (70.3) 113 (72.0) 8 (53.3) 0.131
Migraine history, n (%) 17 (9.9) 17 (11.0) 0 (0.0) 0.368
Circadian rhythmicity in headache attacks, n (%) 103 (59.9) 96 (61.1) 7 (46.7) 0.426
Circannual rhythmicity in headache attacks, n (%) 170 (98.8) 155 (98.7) 15 (100.0) 1.000
Current smoking, n (%) 80 (46.5) 75 (47.8) 5 (33.3) 0.417
Location of pain
 Orbital, n (%) 137 (79.7) 127 (80.9) 10 (66.7) 0.191
 Supraorbital, n (%) 84 (48.8) 78 (49.7) 6 (40.0) 0.474
 Temporal, n (%) 92 (53.5) 84 (53.5) 8 (53.3) 0.990
 Headache Impact Test-6 score, median and IQR 69.0 (63.0–75.0) 69.0 (63.0–75.0) 70.0 (64.0–76.0) 0.938
 Anxiety (Generalized Anxiety Disorder-7 score), median and 
IQR 7.0 (3.0–11.8) 8.0 (3.0–12.0) 2.0 (1.0–6.0) 0.001
 Generalized Anxiety Disorder-7 score ≥ 10, n (%) 81 (37.5) 78 (39.6) 3 (15.8) 0.050
 Depression (Patient Health Questionnaire-9 score), median 
and IQR 6.0 (3.0–11.0) 7.0 (3.0–11.0) 3.0 (1.0–7.0) 0.036
 Patient Health Questionnaire-9 score ≥ 10, n (%) 71 (32.9) 68 (34.5) 3 (15.8) 0.040
 Quality of life (EQ-5D-3L), median and IQR 0.913 (0.819–1.000) 0.913 (0.819–1.000) 0.913 (0.907–1.000) 0.087
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Conjunctival injection and/or lacrimation has been consistently reported to be the most common CAS in 
individuals with  CH8,36–38. In the present study, conjunctival injection and/or lacrimation, as the most frequent 
CAS, was observed in 86.6% of participants with CH. Conjunctival injection and/or lacrimation was the most 
frequent CAS in Asian as well as Western  countries6,22,39,40. The frequency of CAS in the present study was similar 
to that found in previous studies from Asian countries. The frequency of ptosis or miosis in the present study 
(22.2%) was lower than that found in studies from Western countries. A prospective clinical study in the UK 
found that 76% of individuals with CH had  ptosis38. A Danish study reported that ptosis was present in 44.8% 
of patients with  CH37. In Asian studies, a lower frequency of ptosis or miosis has been observed—a Japanese 
study showed a ptosis frequency of 8.1%6, while a study at a Chinese tertiary headache centre revealed that ptosis 
or miosis was present in 16.7% of patients with  CH40 and a Korean multicentre study reported a rate of 8.5%39. 
The similarity in CAS frequencies mentioned above suggests that this parameter was correctly evaluated in the 
present study.
Our study had some limitations. First, it was conducted as a multicentre prospective study, but it did not 
represent the whole CH and PCH population. Therefore, our findings should be validated using another dataset 
to enhance the generalisability. Second, we included relatively small samples of patients with PCH and CCH. 
Although we tried to enrol all eligible patients with PCH and CCH over the 3-year study period, the number 
of relevant cases may have been too small for some subgroup analyses. In other words, the statistical power 
was weakened by the limited sample size. Further studies that include a sufficient number of participants with 
PCH and CCH are needed to verify our findings. Third, we used the GAD-7 and PHQ-9 to assess anxiety and 
depression, respectively. However, these instruments only indicate a state of anxiety and depression and cannot 
be used to confirm the diagnosis. Additional analyses diagnosing anxiety and depression according to the fifth 
edition of the Diagnostic and Statistical Manual of Mental Disorders will confirm the relationship of anxiety 
and depression with CAS in CH.
In conclusion, nearly 9% of participants with CH did not have CAS. The prevalence of anxiety and depression 
was lower in these patients than in those with CAS. Other clinical features were similar between participants 
with and without CAS. One-quarter of the participants with PCH did not have CAS and headache intensity 
Table 5.  Clinical features of participants with PCH according to the presence of CAS. CAS cranial autonomic 
symptoms, EQ-5D-3L the 3-level version of EuroQol five-dimension scale, PCH probable cluster headache, 
IQR interquartile range.
Participants with PCH
n = 26
Participants with PCH with CAS
n = 19
Participants with PCH without CAS
n = 7 p value
Female, n (%) 7 (26.9) 4 (21.1) 3 (42.9) 0.340
Age (year), median and IQR 38.5 (33.8–43.3) 40.0 (35.0–44.0) 36.0 (30–43.0) 0.534
Onset age (year), median and IQR 32.0 (28.8–42.3) 32.0 (28.0–42.0) 36.0 (29.0–43.0) 0.572
Height (cm), median and IQR 174.5 (164.8–177.5) 175.0 (165.0–180.0) 169.0 (158.0–175.0) 0.188
Weight (Kg), median and IQR 72.0 (66.0–81.0) 73.0 (68.0–84.0) 69.0 (55.0–72.0) 0.231
Cluster duration (year), median and IQR 1.0 (0.0–6.3) 2.0 (0.0–9.0) 1.0 (0.0–3.0) 0.427
Total number of cluster periods, median and IQR 1.5 (1.0–4.0) 2.0 (1.0–4.0) 1.0 (1.0–2.0) 0.534
Attack frequency per day, median and IQR 1.0 (1.0–2.0) 1.0 (1.0–3.0) 1.0 (1.0–2.0) 0.778
Headache intensity (numeric rating scale), median and IQR 8.5 (7.8–10.0) 9.5 (8.0–10.0) 8.0 (7.0–8.0) 0.015
Attack duration (minutes), median and IQR 60.0 (35.0–180.0) 60.0 (30.0–195.0) 60.0 (60.0–120.0) 0.790
Average cluster period duration (month), median and IQR 3.5 (2.3–4.0) 4.0 (2.0–4.0) 3.0 (2.0–3.0) 0.727
Average remission period (month), median and IQR 23.0 (5.0–29.0) 23.0 (4.0–28.5) 12.0 (6.0–12.0)  > 0.999
Regular attack pattern, n (%) 6 (23.1) 5 (26.3) 1 (14.3)  > 0.999
Migraine history, n (%) 5 (19.2) 3 (15.8) 2 (28.6) 0.588
Circadian rhythm, n (%) 9 (34.6) 5 (27.8) 4 (571) 0.205
Circannual rhythm, n (%) 22 (84.6) 1 (5.6) 2 (28.6) 0.180
Current smoking, n (%) 8 (30.8) 8 (42.1) 0 (0.0) 0.062
Location of pain
 Orbital, n (%) 21 (80.8) 16 (84.2) 5 (71.4) 0.588
 Supraorbital, n (%) 12 (46.2) 10 (52.6) 2 (28.6) 0.391
 Temporal, n (%) 18 (69.2) 11 (57.9) 7 (100.0) 0.062
 Headache Impact Test-6 score, median and IQR 65.5 (57.0–72.0) 67.0 (58.0–76.0) 58.0 (50.0–68.0) 0.107
 Anxiety (Generalized Anxiety Disorder-7 score), median and 
IQR 5.0 (2.0–9.8) 5.0 (3.0–11.0) 4.0 (3.0–8.0) 0.455
 Generalized Anxiety Disorder-7 score ≥ 10, n (%) 6 (23.1) 5 (26.3) 1 (14.3)  > 0.999
 Depression (Patient Health Questionnaire-9 score), median 
and IQR 4.0 (3.5–13.0) 5.5 (3.8–13.8) 4.0 (3.0–8.0) 0.495
 Patient Health Questionnaire-9 score ≥ 10, n (%) 9 (34.6) 8 (42.1) 1 (14.3) 0.357
 Quality of life (EQ-5D-3L), median and IQR 0.913 (0.833–1.000) 0.913 (0.749–1.000) 0.899 (0.862–0.913) 0.427
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was less severe in these participants than in those with CAS. The frequency of anxiety and depression did not 
differ between participants with PCH with and without CAS. Our study proposed that some clinical features 
of CH and PCH differed based on the presence of CAS. The findings of the present study may help enhance the 
understanding of the pathophysiology of CH.
Data availability
The data used in the present study are available from the corresponding author on reasonable request.
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